Prostaglandin E1: Infants With Critical Congenital Heart Defects

Belinda Chan1, Yogen Singh2

  • 1Department of Pediatrics, Division of Neonatology, University of Utah, Salt Lake City, UT.

Neoreviews
|November 30, 2024
PubMed

Insights

Critical congenital heart defects (CHDs) require prompt intervention. Understanding infant hemodynamic physiology during the transition from intrauterine to extrauterine life is crucial for effective management and improved outcomes in neonates with CHDs.

Area of Science:

  • Neonatal cardiology
  • Pediatric cardiac surgery
  • Fetal medicine

Background:

  • Critical congenital heart defects (CHDs) are severe heart conditions requiring immediate intervention.
  • Delayed diagnosis and management of CHDs in infants increase mortality and morbidity.
  • Antenatal screening and fetal echocardiography enhance early detection and perinatal planning.

Purpose of the Study:

  • To review the immediate postnatal care of infants with critical CHDs.
  • To emphasize the importance of understanding hemodynamic physiology during the transition from fetal to neonatal circulation.
  • To highlight management strategies for infants with critical CHDs, focusing on unique physiological challenges.

Main Methods:

  • Literature review of critical congenital heart defects in the perinatal period.
  • Analysis of hemodynamic transitions in neonates with CHDs.
  • Synthesis of current management guidelines and case studies.

Main Results:

  • Early and accurate diagnosis of fetal CHDs improves perinatal management.
  • Postnatal outcomes vary significantly based on CHD type and severity.
  • Tailored management based on individual infant physiology is essential.

Conclusions:

  • A comprehensive understanding of transitional physiology is vital for managing infants with critical CHDs.
  • Multidisciplinary team collaboration is key for optimal perinatal and postnatal care.
  • Individualized care plans informed by specific CHD physiology can improve infant survival and reduce complications.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
150
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
351
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
5